With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.
Year 2015-16 and 2016-17 with the issues involved relating to levy of penalty under section 272A(2)(g) and section 271C of the Income Tax Act, 1961 (“the Act” for short). All the appeals arise from ...
The Philippines is not only known for its stunning landscapes and warm-hearted people but also for its brilliant minds that ...
Nektar Therapeutics NKTR incurred an adjusted loss per share of 15 cents in the fourth quarter of 2024, wider than the Zacks ...